Skip to content
Screener

Denali Therapeutics Inc. DNLI Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
uniQure logo
uniQureQURE
$985.1M+68.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.87B+8.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.1B+88.4%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemJune 30, 2026December 31, 2025
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.01 par value; 400,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 159,755,526 shares and 156,182,177 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1,9241,888
Additional paid-in capital3,142,7473,062,715
Accumulated other comprehensive income (loss)(1,969)682
Accumulated deficit(2,307,524)(2,051,524)
Total stockholders' equity835,1781,013,761
Total liabilities and stockholders’ equity$1,157,955$1,144,854

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s total liabilities & equity?
Denali Therapeutics Inc. (DNLI) reported total liabilities & equity of $1.16B in Q2 2026.
How has Denali Therapeutics Inc.'s total liabilities & equity changed year-over-year?
Denali Therapeutics Inc.'s total liabilities & equity decreased by 0.7% year-over-year, from $1.17B to $1.16B.
What is the long-term trend for Denali Therapeutics Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s total liabilities & equity has grown at a -6.5% compound annual growth rate (CAGR), from $1.6B to $1.14B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Denali Therapeutics Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude